UnitedHealth Group (UNH) Issues Quarterly Earnings Results

UnitedHealth Group (NYSE:UNH) posted its quarterly earnings data on Tuesday. The healthcare conglomerate reported $2.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.09, Bloomberg Earnings reports. The firm had revenue of $52.06 billion during the quarter, compared to the consensus estimate of $51.57 billion. UnitedHealth Group had a return on equity of 21.52% and a net margin of 4.50%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $2.11 EPS.

Shares of UnitedHealth Group (NYSE:UNH) opened at $228.64 on Tuesday. The firm has a market capitalization of $221,060.00, a P/E ratio of 25.98, a P/E/G ratio of 1.54 and a beta of 0.66. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 0.52. UnitedHealth Group has a fifty-two week low of $156.09 and a fifty-two week high of $231.77.

In related news, insider Thomas E. Roos sold 975 shares of the company’s stock in a transaction that occurred on Thursday, October 19th. The stock was sold at an average price of $205.47, for a total value of $200,333.25. Following the sale, the insider now owns 24,630 shares in the company, valued at approximately $5,060,726.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $221.75, for a total value of $5,011,106.50. Following the completion of the sale, the chief executive officer now owns 195,314 shares in the company, valued at approximately $43,310,879.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,630 shares of company stock worth $7,669,416. Insiders own 0.89% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in UnitedHealth Group by 1.2% during the 2nd quarter. BlackRock Inc. now owns 69,430,416 shares of the healthcare conglomerate’s stock valued at $12,873,786,000 after buying an additional 796,654 shares during the last quarter. Vanguard Group Inc. grew its holdings in UnitedHealth Group by 2.5% during the 2nd quarter. Vanguard Group Inc. now owns 64,578,618 shares of the healthcare conglomerate’s stock valued at $11,974,168,000 after buying an additional 1,588,516 shares during the last quarter. FMR LLC grew its holdings in UnitedHealth Group by 2.1% during the 2nd quarter. FMR LLC now owns 56,101,668 shares of the healthcare conglomerate’s stock valued at $10,402,371,000 after buying an additional 1,168,324 shares during the last quarter. Alliancebernstein L.P. grew its holdings in UnitedHealth Group by 2.3% during the 2nd quarter. Alliancebernstein L.P. now owns 7,906,936 shares of the healthcare conglomerate’s stock valued at $1,466,104,000 after buying an additional 174,290 shares during the last quarter. Finally, TIAA CREF Investment Management LLC grew its holdings in UnitedHealth Group by 3.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 5,882,427 shares of the healthcare conglomerate’s stock valued at $1,090,720,000 after buying an additional 223,524 shares during the last quarter. Hedge funds and other institutional investors own 86.09% of the company’s stock.

A number of equities analysts have recently issued reports on UNH shares. Cantor Fitzgerald increased their target price on UnitedHealth Group to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 18th. Wells Fargo & Co reissued an “outperform” rating and set a $245.00 target price (up from $230.00) on shares of UnitedHealth Group in a research note on Wednesday, November 29th. Credit Suisse Group started coverage on UnitedHealth Group in a research note on Thursday, November 2nd. They set an “outperform” rating and a $233.00 target price for the company. ValuEngine downgraded UnitedHealth Group from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Finally, Royal Bank of Canada increased their target price on UnitedHealth Group to $244.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 29th. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and twenty-five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $229.54.

TRADEMARK VIOLATION NOTICE: “UnitedHealth Group (UNH) Issues Quarterly Earnings Results” was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece on another website, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.truebluetribune.com/2018/01/16/unitedhealth-group-unh-issues-quarterly-earnings-results.html.

About UnitedHealth Group

UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.

Earnings History for UnitedHealth Group (NYSE:UNH)

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply